Gallant Stem Cell Banking Update | Shark Tank Season 11

Stem Cell research is a relatively recent medical development, and no one dreamed about taking that technology to our favorite furry friends—until Aaron Hirschhorn started Gallant. Pitching it on Shark Tank Season 11, their company is a stem cell banking service for man’s best friend (and cats, too). Will the sharks love the idea of saving their pets from unnecessary aging complications? Find out in our pitch recap and Gallant update.

Shark Tank Gallant Update

Gallant Update

  • Entrepreneur: Aaron Hirschhorn
  • Business: Stem cell banking for pets
  • Ask: $500,000 for 2% equity
  • Result: $500,000 for 5% equity
  • Shark: Lori Greiner and Anne Wojcicki

Aaron Hirschhorn’s pitch starts off remarkably effective: he walks in with a basket of puppies, and hands one to each shark. He quickly launches into a fast-talking pitch about how in ten years, four out of the five puppies will have age-related diseases and calls in ‘the grim reaper’ to collect all but one of the pups.

It’s a flashy pitch, but it’s effective. Aaron used to suffer from back pain, and it was cured through stem cell treatments. Now, he wants to bring that same cure to pets around the world. He’s partnered with vet offices, which receive the kits to bank your pets’ stem cells and send them in for storage.

The company always wants to pursue stem-cell medicine as well as banking. Perhaps Gallant is one of the best companies to do it, and in the process, they created a great online platform for dogsitting and made a lot of money that way.

He used those funds to hire top veterinary regenerative medicine experts. He’s also pursued four patents that keep competitors from coming up with a similar idea. Vets will take the stem cells when pets are spayed or neutered, and then isolate them for use later in regenerative treatment.

Despite the research and the proof, the sharks are skeptical. Mark Cuban and guest shark Anne Wojcicki are on the fence, and Kevin wants to see the numbers. Apparently, they are losing money on acquisition—that’s because Gallant pays vets about $100 to partake in the stem cell banking process.

Extraction is also costly, for the consumer and the business. This means that they are burning through a lot of funds, which is part of the reason that they raised $10 million to fund their initial research.

Anne is nervous about the high cost and says the company will sink this way. Daymond John drops out, stating that he values Anne’s opinion on this. Despite their misgivings, Kevin O’Leary makes two offers: $500,000 for 2% equity and 2% stock options, or $500,000 for 1% equity and 10% royalty per kit in perpetuity.

Mark is out because he doesn’t think the company has figured it out quite yet. Anne thinks that the company has long-term potential, so she and Lori Greiner decide to go in together at $500,000 for 8% of the company. Aaron counter-offers for 4%, and they counter again for 5%. Aaron has no choice but to accept.

Was teaming up with Anne and Lori a great idea for the company? Find out in our Gallant update.

Gallant is doing well and has increased its yearly revenue to about $2.5 million. That’s a huge leap. They’ve also managed to reduce the costs, making it less costly to bank your pets’ stem cells (though they maintain their $95 annual fee). Gallant has a board of great people and veterinarians behind it that will help it find more success.

Unfortunately, it’s not all good news. During research for our Gallant update, we found that founder Aaron Hirschhorn passed away in 2021 due to a boating accident. Despite this, Gallant is committed to keeping his vision alive.

You can find the other company updates from Season 11 Episode 8 here:

Don’t forget to take a look at our Season 11 products page! We’ve got more company updates from Shark Tank Season 11.